Showing results (241-250 of 344) with videos related to

Sort By:
Pageof 35
Annals of Hematology|November 12, 2015
Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysisTomotaka Suzuki, Shigeru Kusumoto, Taro Yamashita, et al.
Molecular Cancer Therapeutics|September 27, 2012
RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myelomaYuji Shimura, Junya Kuroda, Masaki Ri, et al.
Cancer Science|September 2, 2022
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohortMasaki Ri, Kenshi Suzuki, Tadao Ishida, et al.
Scientific Reports|May 11, 2019
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma CellsHiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, et al.
Cancer Science|July 24, 2019
Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 studyShinsuke Iida, Takashi Watanabe, Morio Matsumoto, et al.
International Journal of Hematology|April 15, 2021
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patientsMorio Matsumoto, Kenshi Suzuki, Junya Kuroda, et al.
International Journal of Hematology|September 6, 2015
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cellsShohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cancer Science|October 29, 2017
Clinical significance of tryptophan catabolism in Hodgkin lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
International Journal of Hematology|December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myelomaHaruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget|March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunitsTakashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
Pageof 35